# Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL

> **NCT04375683** · PHASE3 · UNKNOWN · sponsor: **Zhongda Hospital** · enrollment: 28 (estimated)

## Conditions studied

- Acute Lymphocytic Leukemia, Adult B-Cell
- BCR-ABL1 Fusion Protein Expression

## Interventions

- **DRUG:** Flumatinib

## Key facts

- **NCT ID:** NCT04375683
- **Lead sponsor:** Zhongda Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-01
- **Primary completion:** 2022-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2022-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04375683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04375683, "Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04375683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*